XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
Manman Deng(Xiamen University), Ken H. Young(Duke Medical Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Benjamin M. Parsons(Gundersen Health System), Maurilio Ponzoni(San Raffaele University of Rome), Bing Xu(First Affiliated Hospital of Xiamen University), Feng Zhu(Xuzhou Medical College), Eric D. Hsi(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Zijun Y. Xu‐Monette(Duke University), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Lapo Alinari(University of Milan), April Chiu(Mayo Clinic), Youli Zu(Methodist Hospital), Wayne Tam(Cornell University), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Xiaosheng Fang(Shandong Provincial Hospital), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Jooryung Huh(Asan Medical Center), Mingzhi Zhang(Chinese Academy of Sciences), Yong Li(Baylor College of Medicine), William W.L. Choi(Chinese University of Hong Kong), Jane N. Winter(Northwestern University), Lan V. Pham(Pharmacyclics (United States)), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center)
Cited by 56
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Circular RNAs function as ceRNAs to regulate and control human cancer progression
|Molecular Cancer|2018|1.1k